Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2015 1
2020 1
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
Factors Associated With University Students' Attitude Toward Euthanasia.
Saadeh R, Banat A, AbuZeina D, Al-Bourini T, Abdelqader E, Alrabadi N, Alfaqih MA, Allouh MZ. Saadeh R, et al. Among authors: banat a. Omega (Westport). 2023 May;87(1):20-37. doi: 10.1177/00302228211016219. Epub 2021 May 20. Omega (Westport). 2023. PMID: 34011208
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.
Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E. Atmaca A, et al. Among authors: banat ag. Br J Cancer. 2013 Feb 5;108(2):265-70. doi: 10.1038/bjc.2012.555. Epub 2013 Jan 17. Br J Cancer. 2013. PMID: 23329236 Free PMC article. Clinical Trial.
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Kirschey S, et al. Among authors: banat a. Br J Haematol. 2015 Mar;168(6):824-34. doi: 10.1111/bjh.13234. Epub 2014 Dec 28. Br J Haematol. 2015. PMID: 25546611 Free article. Clinical Trial.
Lessons from the field: Supporting infection prevention and control and antimicrobial stewardship in Amman, Jordan.
Shallal A, Jarrah J, Prentiss T, Suleyman G, Veve MP, Banat A, Zervos J, Mousa AB, Msadeh L, Zerriouh Thneibat FM, Zervos M, Al-Raiby J, Alsawalha L, Zayed B. Shallal A, et al. Among authors: banat a. J Infect Public Health. 2023 Dec;16 Suppl 1:78-81. doi: 10.1016/j.jiph.2023.10.044. Epub 2023 Nov 2. J Infect Public Health. 2023. PMID: 37945495 Free article.